Free Newsletter
SPOTLIGHT: Merck posts $1.6 billion loss
Free newsletter via e-mail
Tools
Merck reported a whopping $1.6 billion loss for the fourth quarter, mostly because of massive accounting charges related to its $4.85 billion Vioxx settlement. During the same period last year, Merck posted a $473.9 million profit. Meanwhile, some Florida patients left out of the Vioxx deal now want in. Report | Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: